Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Remicade | Infliximab | Ulcerative Colitis | Do not list | Complete | ||
| Cortiment | Budesonide | Ulcerative Colitis | Do not reimburse | Complete | ||
| Omvoh | mirikizumab | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zeposia | ozanimod | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Remsima | infliximab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Active | ||
| Xeljanz | tofacitinib | Ulcerative colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imfinzi and Imjudo | durvalumab and tremelimumab | unresectable hepatocellular carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Stivarga | Regorafenib | Unresectable Hepatocellular Carcinoma (HCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imfinzi | Durvalumab | Unresectable Non-Small Cell Lung Cancer (NSCLC) | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 12, 2024